Status:
COMPLETED
Mortality Reduction After Oral Azithromycin Contingency: Mortality Study
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
The Carter Center
Bill and Melinda Gates Foundation
Conditions:
Childhood Mortality
Eligibility:
All Genders
1-60 years
Phase:
PHASE4
Brief Summary
MORDOR was a cluster-randomized placebo controlled trial that assessed the efficacy of mass azithromycin distributions for the prevention of childhood mortality. All communities were subsequently trea...
Detailed Description
Pre-trial treatments: in the original MORDOR trial, communities were randomized to 4 rounds of biannual mass distributions of either azithromycin or placebo (i.e, the first two years of the trial). Al...
Eligibility Criteria
Inclusion
- Communities- All communities eligible for MORDOR (NCT02047981)
- Individuals-All children aged 1-60 months (up to but not including the 5th birthday), as assessed via biannual census
Exclusion
- Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)
Key Trial Info
Start Date :
October 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2020
Estimated Enrollment :
66228 Patients enrolled
Trial Details
Trial ID
NCT03338244
Start Date
October 20 2017
End Date
July 31 2020
Last Update
August 11 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Proctor Foundation
San Francisco, California, United States, 94143-0944
2
The Carter Center
Niamey, Niger